IgA nephropathy trials in China

In China 53 Also abroad 92

53 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Where
Beijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang
Age
18 years and over
People
370
Run by
Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07390123
No phaseTaking people
Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
Where
Beijing
Age
18 years and over
People
30
Run by
Chinese PLA General Hospital
See details and how to joinNCT07585981
Early phase 1Taking people
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
Where
Hangzhou
Age
3 years and over
People
15
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07586267
Phase 2Taking people
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
Where
Guangzhou, Shanghai
Age
18 years and over
People
84
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07354932
Early phase 1Taking people
A Study of YKST02 in Participants With Primary IgA Nephropathy
Where
Wuhan
Age
18 years to 75 years
People
12
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07498673
Phase 2/3Enrolling by invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Where
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Nanchang, Wuxi, Yibin
Age
18 years and over
People
600 worldwide
Run by
Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT05248659
Phase 2Not yet taking people in China
SLN12140 in Adult Participants With IgA Nephropathy in China
Where
Beijing
Age
18 years to 80 years
People
48
Run by
Linno Pharmaceuticals, Inc.
See details and how to joinNCT07553494
Early phase 1Not yet taking people in China
Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
Where
Xi'an
Age
18 years to 65 years
People
15
Run by
Air Force Military Medical University, China
See details and how to joinNCT07535138
No phaseTaking people
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Where
Guangzhou
Age
14 years and over
People
2,000
Run by
Sun Yat-sen University
See details and how to joinNCT02954419
Phase 1/2Taking people
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
Where
Beijing
Age
18 years and over
People
130
Run by
Beijing Mabworks Biotech Co., Ltd.
See details and how to joinNCT07375758
Early phase 1Taking people
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
Where
Hangzhou
Age
3 years and over
People
15
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07507201
Phase 2Not yet taking people in China
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
Where
Beijing
Age
18 years to 74 years
People
90
Run by
Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT07474636
Phase 1Taking people
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Where
Hangzhou
Age
3 years and over
People
15
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07305116
No phaseTaking people
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
Where
Chengdu
Age
18 years to 75 years
People
200
Run by
Sichuan Provincial People's Hospital
See details and how to joinNCT06676007
Early phase 1Taking people
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Where
Hangzhou
Age
3 years and over
People
36
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT06792799
Phase 2Not yet taking people in China
Study of CM313 in Subject With IgA Nephropathy
Where
Beijing
Age
18 years to 75 years
People
106
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT06830395
Phase 4Taking people
Nefecon and Ambrisentan in IgA Nephropathy
Where
Changchun
Age
18 years to 70 years
People
129
Run by
The First Hospital of Jilin University
See details and how to joinNCT07030894
Early phase 1Enrolling by invitation
A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy
Where
Beijing
Age
18 years to 75 years
People
15
Run by
Peking University First Hospital
See details and how to joinNCT07135219
Phase 3Taking people
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Where
Beijing
Age
18 years and over
People
378
Run by
Chengdu Suncadia Medicine Co., Ltd.
See details and how to joinNCT07014826
Phase 3Taking people
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Where
Guangzhou
Age
18 years and over
People
360
Run by
Biocity Biopharmaceutics Co., Ltd.
See details and how to joinNCT06819826
Phase 1/2Not yet taking people in China
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
Where
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning, Ningbo, Shanghai, Wuxi, Xiamen, Xi’an, Xingtai, Yantai, Yinchuan
Age
18 years and over
People
99
Run by
Sinocelltech Ltd.
See details and how to joinNCT06774664
No phaseTaking people
Raman Spectroscopy Diagnosis of Kidney Diseases
Where
Jinan
People
200
Run by
Zunsong Wang
See details and how to joinNCT06760845
No phaseTaking people
Efficacy and Safety of Telitacicept in IgAN
Where
Shanghai
Age
18 years to 70 years
People
118
Run by
Ruijin Hospital
See details and how to joinNCT06654596
Phase 2Not yet taking people in China
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Where
Beijing
Age
18 years to 75 years
People
72
Run by
Wuhan Createrna Science and Technology Co., Ltd
See details and how to joinNCT06687174
Phase 2Taking people
Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Where
Beijing
Age
18 years to 75 years
People
70
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT05775042